Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Subjects 18 Years of Age or Older

A Phase II, Open-Label, Uncontrolled, Single Center Study to Evaluate Safety and Immunogenicity of a Commercially Available Surface Antigen, Inactivated Influenza Vaccine, Formulation 2006-2007, When Administered to Non-Elderly Adult and Elderly Subjects

The present study aims to evaluate safety and immunogenicity of one dose of a commercially available Surface Antigen, Inactivated Influenza Vaccine, Formulation 2006-2007, in non-elderly adult and elderly subjects.

Inclusion Criteria:

• Male and female subjects 18 years of age or older

Exclusion Criteria:

• any auto-immune disease or other serious acute, chronic or progressive disease
• hypersensitivity to eggs, chicken protein, chicken feathers, influenza viral protein, neomycin or polymyxin or any other component of the vaccine
• known or suspected (or high risk of developing) impairment/alteration of immune function
• within the past 7 days any acute disease or infections requiring systemic antibiotic or antiviral therapy
• history of neurological symptoms or signs, or anaphylactic shock following administration of any vaccine